



7 January 2025

**Argent BioPharma Ltd.**  
(Argent BioPharma or the Company)

**Placing to Raise US\$4,500,000**

Argent BioPharma (**RGT**) is a clinical-stage biopharmaceutical company addressing unmet medical needs by developing innovative treatments for central nervous system and immune-related disorders through neuro-immune modulation and advanced nano-medicine technology.

The company announces the successful completion of a US\$4,500,000 (before costs) capital raise (**Placement**) through the subscription of 11,250,000 fully paid ordinary shares at US\$0.40 (~A\$0.64) per share (**Placement Shares**). The Placement participants will also be issued one (1) free attaching warrant for every two (2) Placement Shares subscribed for, exercisable at \$US0.55 (~A\$0.88) with an expiry date of three year from issuance (**Warrants**).

The Placement will be conducted in two tranches. **Tranche 1:** 5,000,000 Placement Shares and 2,500,000 Warrants to be issued immediately, utilising the Company's existing placement capacity under ASX Listing Rules 7.1 and 7.1A. **Tranche 2:** 6,250,000 Placement Shares and 3,125,000 Warrants to be issued subject to shareholder approval at an upcoming general meeting.

Each Placement Share will be issued at a price of US\$0.40 (~A\$0.64), approximately 370% above the 15-day VWAP of A\$0.173, and 377% to the last closing price of A\$0.17 before the stock entered a trading halt on 3 January 2025.

The proceeds from the Placement will support the advancement of Argent BioPharma's drug development pipeline, with a particular focus on progressing **CannEpil®** and its planned clinical studies.

The Company is also conducting a comprehensive strategic review of its operational and administrative functions to ensure the long-term sustainability of its operations, which is following the delisting from the LSE and establishing the work-plan toward a US National Listing.

**Corporate Advisor:** Sputnik Enterprises Ltd acted as the corporate advisor for the Placement and will receive: A cash fee of 5% of the Placement proceeds, and 1,125,000 Warrants, subject to shareholder approval.

—Ends—

Authorised for release by the board of directors, for further information please contact:

**Argent BioPharma**

Roby Zomer

CEO & Managing Director

+61 8 6555 2950

[info@argentbiopharma.com](mailto:info@argentbiopharma.com)

**Argent BioPharma**

Rowan Harland

Company Secretary

+61 8 6555 2950

[info@argentbiopharma.com](mailto:info@argentbiopharma.com)

**Phone**

+61 8 6555 2950

**Email**

[info@argentbiopharma.com](mailto:info@argentbiopharma.com)

**Address**

Suite 1, 295 Rokeby Road,  
Subiaco WA 6008, Australia



## About Argent BioPharma

Argent BioPharma Limited (the “Company”) (ASX: RGT; OTCQB: RGTLF) is an innovative clinical-stage biopharmaceutical company specializing in neuroimmunology, developing advanced nano-medicines to address unmet medical needs in central nervous system (CNS) disorders and immune-related conditions. By leveraging cutting-edge technologies, including the Neuro-Immune Modulatory (NIM) System and its role in coordinating nervous and immune responses, Argent BioPharma’s robust pipeline—featuring lead candidates like CannEpil®, CogniCann®, and CimetrA®—targets complex diseases where effective treatments are lacking. Through a commitment to science-driven innovation and patient-centered outcomes, Argent BioPharma is reshaping the future of care for chronic, inflammatory, and neurodegenerative diseases

Follow us through our social media channels:

LinkedIn: Argent BioPharma

Twitter: @ArgentBioPharma

Facebook: Argent BioPharma

### Phone

+61 8 6555 2950

### Email

[info@argentbiopharma.com](mailto:info@argentbiopharma.com)

### Address

Suite 1, 295 Rokeby Road,  
Subiaco WA 6008, Australia